Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
- Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals.
- By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing.
- A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported.
Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a novel treatment currently undergoing Phase 2a clinical trials aimed at addressing mild to moderate psoriasis.
Psoriasis affects approximately 3% of the adult population aged 20 years or older in the United States, translating to more than 7.5 million individuals. Notably, around 600,000 adults in the United States live with undiagnosed psoriasis. The prevalence is similar between males (2.8%) and females (3.2%). Globally, the condition impacts about 125 million people, or 2–3% of the world’s population (https://nnw.fm/6Xouz ).
Psoriasis is not merely a skin disorder; it is associated with several comorbidities, including psoriatic arthritis, cardiovascular disease and depression. Approximately 30% of individuals with psoriasis develop psoriatic arthritis, a condition that causes joint pain and stiffness. The economic burden of psoriasis in the United States is substantial, with direct and indirect costs estimated to be between $112 billion and $135 billion annually (https://nnw.fm/sLsQG ).
Current treatment options for psoriasis include topical therapies, phototherapy, and systemic medications such as biologics. While these treatments can be effective, they often come with limitations, including side effects, high costs, and the need for long-term administration. Many patients with mild to moderate psoriasis are seeking alternatives that are both effective and have a favorable safety profile.
Soligenix’s SGX302 represents a promising advancement in this context (https://nnw.fm/rz8Ne ). Utilizing synthetic hypericin, SGX302, or HyBryte(TM), is a novel, first-in-class, photodynamic therapy using safe, visible light that targets and treats psoriatic lesions. This approach is distinct from traditional phototherapy, which often relies on ultraviolet (“UV”) light, potentially leading to long-term skin damage. By using visible light, SGX302 aims to mitigate these risks while effectively reducing inflammation and promoting skin healing.
Soligenix has released top-line interim results from its phase 2a clinical trial evaluating SGX302 in patients with mild to moderate psoriasis (https://nnw.fm/gZNkV ). The study demonstrated that SGX302 was well tolerated, with no significant adverse events reported. In interim results, 50% of patients receiving SGX302 were considered “Almost Clear” in the Psoriasis Area and Severity Index (“PASI”) scores compared to baseline, indicating a reduction in both the extent and severity of psoriatic lesions. These findings suggest that SGX302 has the potential to offer a safe and effective treatment option for individuals with mild to moderate psoriasis.
Soligenix continues to build on its broader mission of delivering therapeutic solutions for difficult-to-treat conditions, with SGX302 marking a noteworthy advancement in its pipeline. By focusing on non-immunosuppressive strategies for managing psoriasis, the company is working to fill a critical gap for patients seeking alternatives to current therapies, many of which come with significant long-term risks or limited efficacy.
As the phase 2a trial moves forward, SGX302’s progress remains closely watched by researchers and clinicians alike. Its novel mechanism and promising early results signal a potential shift in how mild to moderate psoriasis is treated, highlighting Soligenix’s role in reshaping the future of dermatologic care through innovation and precision-targeted drug development.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals.
- By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing.
- A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported.
Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a novel treatment currently undergoing Phase 2a clinical trials aimed at addressing mild to moderate psoriasis.
Psoriasis affects approximately 3% of the adult population aged 20 years or older in the United States, translating to more than 7.5 million individuals. Notably, around 600,000 adults in the United States live with undiagnosed psoriasis. The prevalence is similar between males (2.8%) and females (3.2%). Globally, the condition impacts about 125 million people, or 2–3% of the world’s population (https://nnw.fm/6Xouz ).
Psoriasis is not merely a skin disorder; it is associated with several comorbidities, including psoriatic arthritis, cardiovascular disease and depression. Approximately 30% of individuals with psoriasis develop psoriatic arthritis, a condition that causes joint pain and stiffness. The economic burden of psoriasis in the United States is substantial, with direct and indirect costs estimated to be between $112 billion and $135 billion annually (https://nnw.fm/sLsQG ).
Current treatment options for psoriasis include topical therapies, phototherapy, and systemic medications such as biologics. While these treatments can be effective, they often come with limitations, including side effects, high costs, and the need for long-term administration. Many patients with mild to moderate psoriasis are seeking alternatives that are both effective and have a favorable safety profile.
Soligenix’s SGX302 represents a promising advancement in this context (https://nnw.fm/rz8Ne ). Utilizing synthetic hypericin, SGX302, or HyBryte(TM), is a novel, first-in-class, photodynamic therapy using safe, visible light that targets and treats psoriatic lesions. This approach is distinct from traditional phototherapy, which often relies on ultraviolet (“UV”) light, potentially leading to long-term skin damage. By using visible light, SGX302 aims to mitigate these risks while effectively reducing inflammation and promoting skin healing.
Soligenix has released top-line interim results from its phase 2a clinical trial evaluating SGX302 in patients with mild to moderate psoriasis (https://nnw.fm/gZNkV ). The study demonstrated that SGX302 was well tolerated, with no significant adverse events reported. In interim results, 50% of patients receiving SGX302 were considered “Almost Clear” in the Psoriasis Area and Severity Index (“PASI”) scores compared to baseline, indicating a reduction in both the extent and severity of psoriatic lesions. These findings suggest that SGX302 has the potential to offer a safe and effective treatment option for individuals with mild to moderate psoriasis.
Soligenix continues to build on its broader mission of delivering therapeutic solutions for difficult-to-treat conditions, with SGX302 marking a noteworthy advancement in its pipeline. By focusing on non-immunosuppressive strategies for managing psoriasis, the company is working to fill a critical gap for patients seeking alternatives to current therapies, many of which come with significant long-term risks or limited efficacy.
As the phase 2a trial moves forward, SGX302’s progress remains closely watched by researchers and clinicians alike. Its novel mechanism and promising early results signal a potential shift in how mild to moderate psoriasis is treated, highlighting Soligenix’s role in reshaping the future of dermatologic care through innovation and precision-targeted drug development.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
